Naphthylamine Small Molecules for Mitophagy-Linked Kidney Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for kidney diseases, particularly chronic kidney diseases, are ineffective, and there is a lack of drugs targeting mitochondrial dysfunction, which is a key factor in the progression of these diseases.
Innovation Solution
The use of small-molecule compounds with a naphthylamine structure for preventing and treating diseases associated with kidney injury and mitochondrial dysfunction, including administering therapeutically effective amounts of these compounds to subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic kidney diseases, then current standard therapies are applied, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent applies parameter changes by developing novel small-molecule compounds with specific chemical structures (formula I) that differ from conventional treatments. These compounds are designed to target mitochondrial dysfunction through their unique molecular parameters, including the naphthylamine structure and substituent groups, thereby improving therapeutic efficacy for chronic kidney diseases where conventional therapies fail.
2Reliability
If no specific drugs targeting mitochondrial dysfunction are available, then general kidney treatments are used, but the progression of kidney diseases cannot be effectively halted
Solution Approach 1:
The patent applies segmentation by designing compounds with distinct modular structural components in formula (I), including the core naphthylamine structure, various substituent groups (R1-R6), and optional ring structures. This modular approach allows for systematic development of multiple targeted therapies that can be manufactured through standardized synthetic routes, making targeted mitochondrial therapy more accessible.
Data Source
AI summary
The present application discloses use of small-molecule compound having naphthalamine structure. In the present invention, it was found for first time that the general formula I compound can be used to treat diseases associated with kidney injury and diseases associated with mitophagy, and is expected to be an effective special drug for treating the diseases associated with mitophagy and kidney-associated diseases, especially chronic kidney disease.